Catalog4 refs
Adipotide (Prohibitin-TP01)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
SkinCirculationMitochondria
Overview
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
Primary Uses
Adipose mass reduction
Weight loss
Insulin resistance improvement
Non-CNS peripheral fat loss mechanism
Protocol Reference
Dose
0.43 mg/kg (primate research replication); 0.10-0.75 mg/kg (dose-finding research)
Frequency
Once daily
Half-life
Not established
Route
SubQ
Evidence
Emerging
Research Models
Mouseprimates